Nanobiotix S.A.
NBTX Nasdaq Pharmaceutical Preparations Financials FY2018โFY2025
Last close ยท Oct 23, 2026
$29.36
0.6%
Revenue
Total sales reported in the income statement.
$36.8M
vs prior year
Operating margin
Operating income as a share of revenue.
โ33.2%
984.3ย pts
Net income
Profit after all expenses, interest and tax.
โ$27.0M
Free cash flow
Cash from operations minus capital spending.
โ$38.3M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
$1.40T
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On โ$0.56 EPS (TTM)
What Nanobiotix S.A. does
No business description yet.
- Legal name
- Nanobiotix S.A.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F ยท Mar 31, 2026
- Accession ยท CIK
- 0001760854-26-000003
0001760854
Revenue and margins
Nanobiotix S.A. had $36.8M of revenue in fiscal 2025.
FY18
Revenue $4.1M
FY19
Revenue $2.8M
FY20
Revenue $2.9M
FY21
Revenue $3.1M
FY22
Revenue $5.0M
FY23
Revenue $39.2M
FY24
Revenue โ$7.8M
FY25
Revenue $36.8M
FY18
Gross โ
Operating โ864.2%
Net โ872.2%
FCF โ758.9%
FY19
Gross โ
Operating โ1,841.0%
Net โ2,003.7%
FCF โ1,663.1%
FY20
Gross โ
Operating โ1,450.1%
Net โ1,337.2%
FCF โ1,100.1%
FY21
Gross โ
Operating โ1,986.4%
Net โ1,778.0%
FCF โ1,137.1%
FY22
Gross โ
Operating โ977.8%
Net โ1,194.3%
FCF โ778.8%
FY23
Gross โ
Operating โ74.0%
Net โ109.6%
FCF โ35.4%
FY24
Gross โ
Operating 951.1%
Net 947.5%
FCF 283.6%
FY25
Gross โ
Operating โ33.2%
Net โ73.5%
FCF โ104.2%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY18
Net income โ$35.8M
FY19
Net income โ$57.0M
FY20
Net income โ$38.3M
FY21
Net income โ$55.7M
FY22
Net income โ$60.0M
FY23
Net income โ$42.9M
FY24
Net income โ$73.7M
FY25
Net income โ$27.0M
FY18
Diluted EPS โ$1.83
FY19
Diluted EPS โ$2.63
FY20
Diluted EPS โ$1.57
FY21
Diluted EPS โ$1.60
FY22
Diluted EPS โ$1.72
FY23
Diluted EPS โ$1.17
FY24
Diluted EPS โ$1.56
FY25
Diluted EPS โ$0.56
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY18
Return on capital โ
Return on equity โ219.6%
Return on assets โ60.6%
FY19
Return on capital โ
Return on equity โ804.7%
Return on assets โ93.3%
FY20
Return on capital โ
Return on equity โ90.8%
Return on assets โ33.6%
FY21
Return on capital โ
Return on equity โ95.3%
Return on assets โ39.8%
FY22
Return on capital โ
Return on equity โ8,013.8%
Return on assets โ67.0%
FY23
Return on capital โ
Return on equity โ
Return on assets โ51.3%
FY24
Return on capital โ
Return on equity โ
Return on assets โ84.8%
FY25
Return on capital โ
Return on equity โ
Return on assets โ36.1%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$38.3M in fiscal 2025, โ104.2% of revenue. Cash from operations minus capital spending.
FY18
Free cash flow โ$31.2M
FY19
Free cash flow โ$47.3M
FY20
Free cash flow โ$31.5M
FY21
Free cash flow โ$35.6M
FY22
Free cash flow โ$39.1M
FY23
Free cash flow โ$13.8M
FY24
Free cash flow โ$22.1M
FY25
Free cash flow โ$38.3M
FY18
Cash from operations โ$30.7M
Capital spending $0.5M
FY19
Cash from operations โ$46.1M
Capital spending $1.2M
FY20
Cash from operations โ$31.4M
Capital spending $0.1M
FY21
Cash from operations โ$35.3M
Capital spending $0.3M
FY22
Cash from operations โ$39.0M
Capital spending $0.1M
FY23
Cash from operations โ$13.5M
Capital spending $0.4M
FY24
Cash from operations โ$21.2M
Capital spending $0.9M
FY25
Cash from operations โ$37.7M
Capital spending $0.6M
Cash from operations
Capital spending
Dividends, buybacks and share count
Nanobiotix S.A. returned โ to shareholders in fiscal 2025. The diluted share count rose 1.2%.
FY18
Dividends โ
Buybacks โ
FY19
Dividends โ
Buybacks โ
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY18
Diluted shares 19.63B
FY19
Diluted shares 21.63B
FY20
Diluted shares 24.39B
FY21
Diluted shares 34.73B
FY22
Diluted shares 34.85B
FY23
Diluted shares 36.93B
FY24
Diluted shares 47.27B
FY25
Diluted shares 47.82B
Balance sheet
Cash, debt and the ratios that show how comfortably Nanobiotix S.A. can carry it.
FY18
Cash $41.5M
Debt โ
FY19
Cash $39.4M
Debt โ
FY20
Cash $146M
Debt โ
FY21
Cash $95.0M
Debt โ
FY22
Cash $44.1M
Debt โ
FY23
Cash $83.2M
Debt โ
FY24
Cash $51.7M
Debt โ
FY25
Cash $62.0M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $95.0M | $44.1M | $83.2M | $51.7M | $62.0M |
| Interest coverage | โ67.4x | โ3.4x | โ1.8x | โ9.1x | โ0.7x |
| Current ratio | 2.5x | 1.4x | 1.8x | 1.0x | 1.1x |
| Quick ratio | 2.5x | 1.4x | 1.8x | 1.0x | 1.1x |
| Total assets | $115M | $63.7M | $104M | $70.0M | $79.6M |
| Total liabilities | $84.9M | $92.6M | $106M | $138M | $179M |
| Shareholders' equity | $30.3M | โ$28.8M | โ$2.0M | โ$68.3M | โ$99.3M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | 1 / 7 | 3 / 7 | 2 / 7 | 2 / 7 | 4 / 7 | 1 / 7 | 3 / 7 |
| Accruals ratio | โ8.7% | โ17.9% | โ6.1% | โ14.5% | โ23.4% | โ35.2% | โ60.5% | 14.3% |
| Altman Z'' | โ | โ | โ | โ5.50 | โ16.32 | โ8.89 | โ25.76 | โ20.39 |
8 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.1M | $2.8M | $2.9M | $3.1M | $5.0M | $39.2M | โ$7.8M | $36.8M |
| Net interest income | โ | โ$5.0M | $5.3M | โ$0.5M | โ$5.9M | โ$8.4M | โ$8.6M | โ$11.6M |
| Research and development | $24.7M | $34.0M | $27.7M | $35.9M | $34.3M | $41.5M | $43.9M | $26.1M |
| Operating income | โ$35.5M | โ$52.4M | โ$41.5M | โ$62.2M | โ$49.1M | โ$29.0M | โ$74.0M | โ$12.2M |
| Interest expense | $1.0M | $5.0M | โ$5.3M | $0.9M | $14.6M | $16.0M | $8.1M | $17.2M |
| Pretax income | โ$35.8M | โ$57.0M | โ$38.3M | โ$55.6M | โ$60.0M | โ$42.9M | โ$73.7M | โ$27.0M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.0M |
| Net income | โ$35.8M | โ$57.0M | โ$38.3M | โ$55.7M | โ$60.0M | โ$42.9M | โ$73.7M | โ$27.0M |
| Net income to common | โ$35.8M | โ$57.0M | โ$38.3M | โ$55.7M | โ$60.0M | โ$42.9M | โ$73.7M | โ$27.0M |
| Diluted EPS | โ$1.83 | โ$2.63 | โ$1.57 | โ$1.60 | โ$1.72 | โ$1.17 | โ$1.56 | โ$0.56 |
| Diluted shares | 19.63B | 21.63B | 24.39B | 34.73B | 34.85B | 36.93B | 47.27B | 47.82B |
| Cash flow | ||||||||
| Cash from operations | โ$30.7M | โ$46.1M | โ$31.4M | โ$35.3M | โ$39.0M | โ$13.5M | โ$21.2M | โ$37.7M |
| Capital expenditure | $0.5M | $1.2M | $0.1M | $0.3M | $0.1M | $0.4M | $0.9M | $0.6M |
| Free cash flow | โ$31.2M | โ$47.3M | โ$31.5M | โ$35.6M | โ$39.1M | โ$13.8M | โ$22.1M | โ$38.3M |
| Depreciation and amortization | $0.7M | $2.0M | $2.0M | $1.8M | $1.6M | $1.6M | $1.8M | $1.7M |
| Stock-based compensation | $2.2M | $4.8M | $3.3M | $3.8M | $3.3M | $3.5M | $4.6M | $4.0M |
| Balance sheet | ||||||||
| Cash and short-term investments | $41.5M | $39.4M | $146M | $95.0M | $44.1M | $83.2M | $51.7M | $62.0M |
| Current assets | $48.7M | $51.8M | $154M | $105M | $55.8M | $96.5M | $63.9M | $73.7M |
| Current liabilities | $13.9M | $16.1M | $23.4M | $41.7M | $40.5M | $55.1M | $61.2M | $67.6M |
| Property and equipment, net | $9.6M | $10.5M | $10.1M | $9.3M | $7.6M | $6.9M | $5.8M | $5.4M |
| Intangible assets | $0.1M | $0.2M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Total assets | $59.1M | $63.1M | $164M | $115M | $63.7M | $104M | $70.0M | $79.6M |
| Total liabilities | $42.8M | $65.3M | $78.0M | $84.9M | $92.6M | $106M | $138M | $179M |
| Shareholders' equity | $16.3M | โ$2.1M | $86.5M | $30.3M | โ$28.8M | โ$2.0M | โ$68.3M | โ$99.3M |
| Margins | ||||||||
| Operating margin | โ864.2% | โ1,841.0% | โ1,450.1% | โ1,986.4% | โ977.8% | โ74.0% | 951.1% | โ33.2% |
| EBITDA margin | โ846.4% | โ1,771.4% | โ1,380.3% | โ1,927.4% | โ946.4% | โ69.8% | 928.5% | โ28.6% |
| Net margin | โ872.2% | โ2,003.7% | โ1,337.2% | โ1,778.0% | โ1,194.3% | โ109.6% | 947.5% | โ73.5% |
| FCF margin | โ758.9% | โ1,663.1% | โ1,100.1% | โ1,137.1% | โ778.8% | โ35.4% | 283.6% | โ104.2% |
| Net interest share of revenue | โ | โ174.5% | 186.1% | โ14.5% | โ117.2% | โ21.5% | 110.1% | โ31.5% |
| Returns | ||||||||
| Return on capital employed | โ78.6% | โ111.4% | โ29.4% | โ84.6% | โ210.8% | โ59.5% | โ839.5% | โ101.3% |
| Return on equity | โ219.6% | โ804.7% | โ90.8% | โ95.3% | โ8,013.8% | โ | โ | โ |
| Return on assets | โ60.6% | โ93.3% | โ33.6% | โ39.8% | โ67.0% | โ51.3% | โ84.8% | โ36.1% |
| Return on tangible equity | โ221.1% | โ | โ44.3% | โ183.5% | โ | โ | โ | โ |
| Growth | ||||||||
| Revenue growth | โ | โ30.7% | 0.7% | 9.3% | 60.3% | 680.0% | โ119.9% | โ |
| Share count change | โ | 10.2% | 12.7% | 42.4% | 0.3% | 6.0% | 28.0% | 1.2% |
| Financial health | ||||||||
| Interest coverage | โ35.5x | โ10.6x | โ | โ67.4x | โ3.4x | โ1.8x | โ9.1x | โ0.7x |
| Current ratio | 3.5x | 3.2x | 6.6x | 2.5x | 1.4x | 1.8x | 1.0x | 1.1x |
| Quick ratio | 3.5x | 3.2x | 6.6x | 2.5x | 1.4x | 1.8x | 1.0x | 1.1x |
| Capital allocation | ||||||||
| Capex / revenue | 12.0% | 42.9% | 3.8% | 8.6% | 1.9% | 0.9% | โ11.8% | 1.7% |
| Stock comp / revenue | 53.7% | 170.0% | 116.4% | 120.9% | 66.5% | 8.9% | โ59.8% | 10.9% |
| Quality scores | ||||||||
| Piotroski F-score | โ | 1.0 | 3.0 | 2.0 | 2.0 | 4.0 | 1.0 | 3.0 |
| Altman Z'' | โ | โ | โ | โ5.5 | โ16.3 | โ8.9 | โ25.8 | โ20.4 |
| Accruals ratio | โ8.7% | โ17.9% | โ6.1% | โ14.5% | โ23.4% | โ35.2% | โ60.5% | 14.3% |
Source: SEC EDGAR XBRL filings (CIK 0001760854). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only โ not investment advice. Check the original filings before relying on any figure.